328 related articles for article (PubMed ID: 23644885)
1. Targeting signaling pathways in epithelial ovarian cancer.
Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J
Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885
[TBL] [Abstract][Full Text] [Related]
2. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
4. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
6. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
Weberpals JI; Koti M; Squire JA
Cancer Genet; 2011 Oct; 204(10):525-35. PubMed ID: 22137482
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
8. Epithelial ovarian cancer: focus on targeted therapy.
Pliarchopoulou K; Pectasides D
Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for systemic therapy in ovarian cancer.
Penzvalto Z; Surowiak P; Gyorffy B
Curr Cancer Drug Targets; 2014; 14(3):259-73. PubMed ID: 24605893
[TBL] [Abstract][Full Text] [Related]
10. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
Martín de la Fuente L; Malander S; Hartman L; Jönsson JM; Ebbesson A; Nilbert M; Måsbäck A; Hedenfalk I
Int J Gynecol Pathol; 2018 Mar; 37(2):101-109. PubMed ID: 28481779
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
15. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
16. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
17. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
Liu N; Wang X; Sheng X
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
[TBL] [Abstract][Full Text] [Related]
18. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]